Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice

Mohammad Ali Danesh-Bahreini1,5, Javad Shokri1,2, Afshin Samiei3, Eskandar Kamali-Sarvestani4, Mohammad Barzegar-Jalali1, Soliman Mohammadi-Samani41Department of Pharmaceutics, 2Research Center for Pharmaceutical Nanotechnology, School of Pharmacy, Tabriz University of Medical Science, Tabriz, Iran;...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Danesh-Bahreini MA, Shokri J, Samiei A, Kamali-Sarvestani E, Barzegar-Jalali M, Mohammadi-Samani S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c7e80b9737eb40b9a4a258b513efbc35
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c7e80b9737eb40b9a4a258b513efbc35
record_format	dspace
spelling	oai:doaj.org-article:c7e80b9737eb40b9a4a258b513efbc352021-12-02T01:13:37ZNanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice1176-91141178-2013https://doaj.org/article/c7e80b9737eb40b9a4a258b513efbc352011-04-01T00:00:00Zhttp://www.dovepress.com/nanovaccine-for-leishmaniasis-preparation-of-chitosan-nanoparticles-co-a7171https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Mohammad Ali Danesh-Bahreini1,5, Javad Shokri1,2, Afshin Samiei3, Eskandar Kamali-Sarvestani4, Mohammad Barzegar-Jalali1, Soliman Mohammadi-Samani41Department of Pharmaceutics, 2Research Center for Pharmaceutical Nanotechnology, School of Pharmacy, Tabriz University of Medical Science, Tabriz, Iran; 3Autoimmune Diseases Research Center, School of Medicine, 4Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Science, Shiraz, Iran; 5Research and Development Department, Exir Pharmaceutical Company, Borujerd, IranBackground: Leishmaniasis is a protozoan disease, affecting 12 million people in different regions of the world with a wide spectrum of diseases. Although several chemotherapeutic agents have been used for treating the disease, long-term therapy, limited efficacy and the development of drug-resistant parasites remain the major limitations.Methods: To develop a new nanovaccine for leishmaniasis, recombinant Leishmania superoxide dismutase (SODB1) was loaded onto chitosan nanoparticles by the ionotropic gelation method. Size and loading efficiency of the nanoparticles were evaluated and optimized, and an immunization study was undertaken on BALB/c mice. The mice received phosphate buffer saline (PBS), superoxide dismutase B1 (SODB1) in PBS and nanoparticles via subcutaneous injection. Soluble Leishmania Antigens (SLA) and complete Freund&rsquo;s adjuvant (CFA) were also injected subcutaneously three times every three weeks (some groups received only a single dose). Three weeks after the last injection, blood samples were collected and assessed with ELISA to detect IgG2a and IgG1.Results: Immunological analysis showed that in single and triple doses of SODB1 nanoparticles, IgG2a and IgG2a/IgG1 were significantly higher than the other groups (P&lt;0.05).Conclusion: The results revealed that formulations of SODB1 in biodegradable and stable chitosan nanoparticles can increase the immunogenicity toward cell-mediated immunity (TH1 cells producing IgG2a in mice) that is effective in Leishmania eradication and could be presented as a single dose nanovaccine for leishmaniasis.Keywords: chitosan nanoparticles, leishmaniasis, vaccine, superoxide dismutase Danesh-Bahreini MAShokri JSamiei AKamali-Sarvestani EBarzegar-Jalali MMohammadi-Samani SDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2011, Iss default, Pp 835-842 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Danesh-Bahreini MA Shokri J Samiei A Kamali-Sarvestani E Barzegar-Jalali M Mohammadi-Samani S Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice
description	Mohammad Ali Danesh-Bahreini1,5, Javad Shokri1,2, Afshin Samiei3, Eskandar Kamali-Sarvestani4, Mohammad Barzegar-Jalali1, Soliman Mohammadi-Samani41Department of Pharmaceutics, 2Research Center for Pharmaceutical Nanotechnology, School of Pharmacy, Tabriz University of Medical Science, Tabriz, Iran; 3Autoimmune Diseases Research Center, School of Medicine, 4Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Science, Shiraz, Iran; 5Research and Development Department, Exir Pharmaceutical Company, Borujerd, IranBackground: Leishmaniasis is a protozoan disease, affecting 12 million people in different regions of the world with a wide spectrum of diseases. Although several chemotherapeutic agents have been used for treating the disease, long-term therapy, limited efficacy and the development of drug-resistant parasites remain the major limitations.Methods: To develop a new nanovaccine for leishmaniasis, recombinant Leishmania superoxide dismutase (SODB1) was loaded onto chitosan nanoparticles by the ionotropic gelation method. Size and loading efficiency of the nanoparticles were evaluated and optimized, and an immunization study was undertaken on BALB/c mice. The mice received phosphate buffer saline (PBS), superoxide dismutase B1 (SODB1) in PBS and nanoparticles via subcutaneous injection. Soluble Leishmania Antigens (SLA) and complete Freund&rsquo;s adjuvant (CFA) were also injected subcutaneously three times every three weeks (some groups received only a single dose). Three weeks after the last injection, blood samples were collected and assessed with ELISA to detect IgG2a and IgG1.Results: Immunological analysis showed that in single and triple doses of SODB1 nanoparticles, IgG2a and IgG2a/IgG1 were significantly higher than the other groups (P&lt;0.05).Conclusion: The results revealed that formulations of SODB1 in biodegradable and stable chitosan nanoparticles can increase the immunogenicity toward cell-mediated immunity (TH1 cells producing IgG2a in mice) that is effective in Leishmania eradication and could be presented as a single dose nanovaccine for leishmaniasis.Keywords: chitosan nanoparticles, leishmaniasis, vaccine, superoxide dismutase
format	article
author	Danesh-Bahreini MA Shokri J Samiei A Kamali-Sarvestani E Barzegar-Jalali M Mohammadi-Samani S
author_facet	Danesh-Bahreini MA Shokri J Samiei A Kamali-Sarvestani E Barzegar-Jalali M Mohammadi-Samani S
author_sort	Danesh-Bahreini MA
title	Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice
title_short	Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice
title_full	Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice
title_fullStr	Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice
title_full_unstemmed	Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice
title_sort	nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing leishmania superoxide dismutase and evaluation of its immunogenicity in balb/c mice
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/c7e80b9737eb40b9a4a258b513efbc35
work_keys_str_mv	AT daneshbahreinima nanovaccineforleishmaniasispreparationofchitosannanoparticlescontainingleishmaniasuperoxidedismutaseandevaluationofitsimmunogenicityinbalbcmice AT shokrij nanovaccineforleishmaniasispreparationofchitosannanoparticlescontainingleishmaniasuperoxidedismutaseandevaluationofitsimmunogenicityinbalbcmice AT samieia nanovaccineforleishmaniasispreparationofchitosannanoparticlescontainingleishmaniasuperoxidedismutaseandevaluationofitsimmunogenicityinbalbcmice AT kamalisarvestanie nanovaccineforleishmaniasispreparationofchitosannanoparticlescontainingleishmaniasuperoxidedismutaseandevaluationofitsimmunogenicityinbalbcmice AT barzegarjalalim nanovaccineforleishmaniasispreparationofchitosannanoparticlescontainingleishmaniasuperoxidedismutaseandevaluationofitsimmunogenicityinbalbcmice AT mohammadisamanis nanovaccineforleishmaniasispreparationofchitosannanoparticlescontainingleishmaniasuperoxidedismutaseandevaluationofitsimmunogenicityinbalbcmice
_version_	1718403223774035968

Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice

Ejemplares similares